Companies › Biotechnology Institute IMASD
1 active drug program in 2 registered trials: 2 Phase 4; Metabolic and endocrine, Other; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Plasma Rich in Growth Factors (PRGF) Growth factor-enriched autologous plasma injection | – | Phase 4 | Diseases [C] - Musculoskeletal Diseases [C05; Foot Ulcers, Diabetic | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06715085 | Plasma Rich in Growth Factors (PRGF) | Phase 4 | Diseases [C] - Musculoskeletal Diseases [C05 | Other | Feb 2027 |
| NCT06952998 | Plasma Rich in Growth Factors (PRGF) | Phase 4 | Foot Ulcers, Diabetic | Metabolic and endocrine | May 2027 |
No annotated target.
–
Soleno Therapeutics Energenesis Biomedical BrightGene Bio-Medical Technology Fresenius Kabi Huons Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.